FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:CCDC6-UBE2D1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: CCDC6-UBE2D1
FusionPDB ID: 13898
FusionGDB2.0 ID: 13898
HgeneTgene
Gene symbol

CCDC6

UBE2D1

Gene ID

8030

7321

Gene namecoiled-coil domain containing 6ubiquitin conjugating enzyme E2 D1
SynonymsD10S170|H4|PTC|TPC|TST1E2(17)KB1|SFT|UBC4/5|UBCH5|UBCH5A
Cytomap

10q21.2

10q21.1

Type of geneprotein-codingprotein-coding
Descriptioncoiled-coil domain-containing protein 6papillary thyroid carcinoma-encoded proteinubiquitin-conjugating enzyme E2 D1(E3-independent) E2 ubiquitin-conjugating enzyme D1E2 ubiquitin-conjugating enzyme D1UBC4/5 homologstimulator of Fe transportubiquitin carrier protein D1ubiquitin conjugating enzyme E2D 1ubiquitin-conjugating enzym
Modification date2020032720200313
UniProtAcc

A6NI79

Main function of 5'-partner protein: FUNCTION: May act as a scaffold to regulate the recruitment and assembly of spindle midzone components. Required for the localization of AURKB and PLK1 to the spindle midzone. {ECO:0000305|PubMed:20962590}.
.
Ensembl transtripts involved in fusion geneENST idsENST00000263102, ENST00000373910, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score15 X 22 X 10=33005 X 4 X 3=60
# samples 385
** MAII scorelog2(38/3300*10)=-3.11839470080223
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/60*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: CCDC6 [Title/Abstract] AND UBE2D1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: CCDC6 [Title/Abstract] AND UBE2D1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)CCDC6(61665880)-UBE2D1(60121098), # samples:2
Anticipated loss of major functional domain due to fusion event.CCDC6-UBE2D1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CCDC6-UBE2D1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
CCDC6-UBE2D1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
CCDC6-UBE2D1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneUBE2D1

GO:0000209

protein polyubiquitination

15247280|16275645

TgeneUBE2D1

GO:0006511

ubiquitin-dependent protein catabolic process

16275645

TgeneUBE2D1

GO:0031398

positive regulation of protein ubiquitination

16275645

TgeneUBE2D1

GO:0070936

protein K48-linked ubiquitination

20061386



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr10:61665880/chr10:60121098)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across CCDC6 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across UBE2D1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000263102CCDC6chr1061665880-ENST00000373910UBE2D1chr1060121098+2943535109954281

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000263102ENST00000373910CCDC6chr1061665880-UBE2D1chr1060121098+0.0003620290.99963796

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for CCDC6-UBE2D1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
CCDC6chr1061665880UBE2D1chr1060121098535142EENRDLRKASVTIELSDLQRDPPAHC

Top

Potential FusionNeoAntigen Information of CCDC6-UBE2D1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CCDC6-UBE2D1_61665880_60121098.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:07RKASVTIEL0.99880.6539615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:01RKASVTIEL0.95920.8939615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B38:01RKASVTIEL0.9310.9468615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:13RKASVTIEL0.89980.9155615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B38:02RKASVTIEL0.86330.949615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B48:01RKASVTIEL0.81230.65615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B15:03RKASVTIEL0.63770.8801615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B15:10RKASVTIEL0.63050.6622615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B47:01RKASVTIEL0.25270.759615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:07LRKASVTIEL0.99890.7416515
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C03:08KASVTIEL0.99990.9273715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C15:06KASVTIEL0.99990.9473715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C03:19KASVTIEL0.99990.9946715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C08:04KASVTIEL0.99520.9806715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C08:13KASVTIEL0.99520.9806715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C02:06KASVTIEL0.99430.9845715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C08:03KASVTIEL0.89150.9898715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:95RKASVTIEL0.99750.6776615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:05RKASVTIEL0.99040.9647615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:12RKASVTIEL0.98370.8969615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:27RKASVTIEL0.98340.9597615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:13RKASVTIEL0.97780.9465615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:09RKASVTIEL0.97580.6211615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:29RKASVTIEL0.96260.9359615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:05RKASVTIEL0.82970.88615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:80RKASVTIEL0.82140.9508615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:67RKASVTIEL0.82140.9508615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:46RKASVTIEL0.8160.8911615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:19RKASVTIEL0.8130.7842615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:10RKASVTIEL0.80870.9654615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:08RKASVTIEL0.71750.8432615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C12:16RKASVTIEL0.09110.9568615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C15:05KASVTIEL0.99990.9063715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C15:02KASVTIEL0.99990.9185715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C03:17KASVTIEL0.99990.9835715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C03:05KASVTIEL0.99990.9515715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C03:04KASVTIEL0.99960.9943715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C03:03KASVTIEL0.99960.9943715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C16:02KASVTIEL0.99840.9932715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C16:04KASVTIEL0.99460.9782715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C17:01KASVTIEL0.99050.9717715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C16:01KASVTIEL0.98710.979715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B35:13KASVTIEL0.94720.9278715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B07:13KASVTIEL0.90480.8417715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C08:01KASVTIEL0.89150.9898715
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:06RKASVTIEL0.99920.8997615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:09RKASVTIEL0.99880.949615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:01RKASVTIEL0.99770.6861615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:02RKASVTIEL0.98680.9161615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:31RKASVTIEL0.95710.8941615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B38:05RKASVTIEL0.9310.9468615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:22RKASVTIEL0.88660.7017615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:02RKASVTIEL0.82140.9508615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:17RKASVTIEL0.81390.9603615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C06:08RKASVTIEL0.77270.9932615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B39:11RKASVTIEL0.6940.7655615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C07:04RKASVTIEL0.64790.9632615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B48:02RKASVTIEL0.63920.9468615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C06:06RKASVTIEL0.56480.9913615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B15:09RKASVTIEL0.4970.8221615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C06:02RKASVTIEL0.18230.9935615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-C06:17RKASVTIEL0.18230.9935615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B15:68RKASVTIEL0.14020.7424615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B15:54RKASVTIEL0.09890.9189615
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:08LRKASVTIEL0.99950.9565515
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:06LRKASVTIEL0.99940.9493515
CCDC6-UBE2D1chr1061665880chr1060121098535HLA-B27:09LRKASVTIEL0.99910.9736515

Top

Potential FusionNeoAntigen Information of CCDC6-UBE2D1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
CCDC6-UBE2D1_61665880_60121098.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
CCDC6-UBE2D1chr1061665880chr1060121098535DRB1-0413KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB1-0422KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB1-0470KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0101KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0101RKASVTIELSDLQRD621
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0101ASVTIELSDLQRDPP823
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0103KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0103RKASVTIELSDLQRD621
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0103ASVTIELSDLQRDPP823
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0104KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0104RKASVTIELSDLQRD621
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0104ASVTIELSDLQRDPP823
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0104LRKASVTIELSDLQR520
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0106KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0106RKASVTIELSDLQRD621
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0106ASVTIELSDLQRDPP823
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0107KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0107RKASVTIELSDLQRD621
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0107ASVTIELSDLQRDPP823
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0108KASVTIELSDLQRDP722
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0108RKASVTIELSDLQRD621
CCDC6-UBE2D1chr1061665880chr1060121098535DRB4-0108ASVTIELSDLQRDPP823

Top

Fusion breakpoint peptide structures of CCDC6-UBE2D1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
7958RKASVTIELSDLQRCCDC6UBE2D1chr1061665880chr1060121098535

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of CCDC6-UBE2D1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN7958RKASVTIELSDLQR-7.9962-8.1096
HLA-B14:023BVN7958RKASVTIELSDLQR-5.70842-6.74372
HLA-B52:013W397958RKASVTIELSDLQR-6.83737-6.95077
HLA-B52:013W397958RKASVTIELSDLQR-4.4836-5.5189
HLA-A11:014UQ27958RKASVTIELSDLQR-10.0067-10.1201
HLA-A11:014UQ27958RKASVTIELSDLQR-9.03915-10.0745
HLA-A24:025HGA7958RKASVTIELSDLQR-6.56204-6.67544
HLA-A24:025HGA7958RKASVTIELSDLQR-5.42271-6.45801
HLA-B44:053DX87958RKASVTIELSDLQR-7.85648-8.89178
HLA-B44:053DX87958RKASVTIELSDLQR-5.3978-5.5112
HLA-A02:016TDR7958RKASVTIELSDLQR-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of CCDC6-UBE2D1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
CCDC6-UBE2D1chr1061665880chr1060121098515LRKASVTIELCTGCGCAAAGCCAGCGTGACCATCGAATTG
CCDC6-UBE2D1chr1061665880chr1060121098615RKASVTIELCGCAAAGCCAGCGTGACCATCGAATTG
CCDC6-UBE2D1chr1061665880chr1060121098715KASVTIELAAAGCCAGCGTGACCATCGAATTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
CCDC6-UBE2D1chr1061665880chr1060121098520LRKASVTIELSDLQRCTGCGCAAAGCCAGCGTGACCATCGAATTGAGTGATCTACAGCGC
CCDC6-UBE2D1chr1061665880chr1060121098621RKASVTIELSDLQRDCGCAAAGCCAGCGTGACCATCGAATTGAGTGATCTACAGCGCGAT
CCDC6-UBE2D1chr1061665880chr1060121098722KASVTIELSDLQRDPAAAGCCAGCGTGACCATCGAATTGAGTGATCTACAGCGCGATCCA
CCDC6-UBE2D1chr1061665880chr1060121098823ASVTIELSDLQRDPPGCCAGCGTGACCATCGAATTGAGTGATCTACAGCGCGATCCACCT

Top

Information of the samples that have these potential fusion neoantigens of CCDC6-UBE2D1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCACCDC6-UBE2D1chr1061665880ENST00000263102chr1060121098ENST00000373910TCGA-AO-A0J6-01A

Top

Potential target of CAR-T therapy development for CCDC6-UBE2D1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to CCDC6-UBE2D1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to CCDC6-UBE2D1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource
HgeneCCDC6C0238463Papillary thyroid carcinoma2CTD_human;ORPHANET
HgeneCCDC6C3501843Nonmedullary Thyroid Carcinoma1CTD_human
HgeneCCDC6C3501844Familial Nonmedullary Thyroid Cancer1CTD_human